Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF)

General Information Age Group Adults Status Active Protocol Number [18-2997] Background Information The objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on long-term clinical outcomes among patients hospitalized for heart failure. All patients will be followed for a minimum of 12 months. Offered At Inova Fairfax Hospital 3300 Gallows Road Falls Church, VA 22042 Principal Investigator Mitchell Psotka, MD, PhD Eligibility Information Patient hospitalized (≥ 24 hours or over a change in calendar date) with worsening of chronic heart failure, or new diagnosis of heart failure AND meets 1 of the following criteria: Has a left ventricular ejection fraction (EF) ≤ 40% within 24 months prior to and including index hospitalization by any method (with most recent value used to determine eligibility) Has an elevated natriuretic peptide level (either NT-pro-B-type natriuretic peptide or B-type natriuretic peptide) during index hospitalization as measured by local laboratory Plan for a daily outpatient oral loop diuretic regimen upon hospital discharge with anticipated need for long-term loop diuretic use ≥ 18 years of age Signed informed consent Ineligibility Information End-stage renal disease requiring dialysis therapy Inability or unwillingness to comply with the study requirements History of heart transplant or actively listed for heart transplant Implanted left ventricular assist device or implant anticipated < 3 months Pregnant or nursing women or women who are trying to conceive Malignancy or other non-cardiac condition limiting life expectancy to < 12 months Known hypersensitivity to furosemide, torsemide, or related agents For additional information, please visit: https://clinicaltrials.gov/ct2/show/NCT03296813 Contact Information Contact Name Van Doan Contact Phone 703-776-8008 Contact Email Send Email